7 terminated. 7 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Terminated 7 |
| Phase 1 | 3 | Terminated 3 |
| Phase 3 | 1 | Terminated 1 |
Follow Sarcoma, Synovial: new trials by email Literature Review of Sarcoma, Synovial trials Research Report on Sarcoma, Synovial
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma Ramucirumab, Gemcitabine, Docetaxel - Synovial Sarcoma | Phase 1 / Phase 2 | Terminated | Eli Lilly and Company | 23 | 2020-03-04 | 2023-09-13 |
| A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study Tazemetostat - Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) | Phase 1 / Phase 2 | Terminated | Epizyme, Inc. | 58 | 2016-08-30 | 2026-10-28 |
| Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Pazopanib, Pazopanib Hydrochloride, Sapanisertib - High Grade Sarcoma, Metastatic Leiomyosarcoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 151 | 2015-11-30 | 2022-08-23 |
| Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002) CMB305, atezolizumab - Sarcoma, Myxoid/Round Cell Liposarcoma | Phase 2 | Terminated | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 89 | 2015-04-29 | 2020-07-07 |
| Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma doxorubicin hydrochloride, trabectedin, laboratory biomarker analysis - Sarcoma | Phase 2 / Phase 3 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 133 | 2011-05-01 | 2014-08-08 |
| A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g) PRO95780 - Chondrosarcoma | Phase 2 | Terminated | Genentech, Inc. | 15 | 2007-05-31 | 2022-12-13 |
| A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma ipilimumab - Synovial Sarcoma | Phase 2 | Terminated | Ludwig Institute for Cancer Research | 6 | 2005-06-08 | 2022-10-12 |
Sarcoma (6) · Histiocytoma, Malignant Fibrous (2) · Leiomyosarcoma (2) · Neurofibrosarcoma (2) · Chondrosarcoma (1) · Chondrosarcoma, Extraskeletal Myxoid (1) · Dermatofibrosarcoma (1) · Desmoplastic Small Round Cell Tumor (1) · Fibrosarcoma (1) · Hemangiopericytoma, Malignant (1) · Hemangiosarcoma (1) · Liposarcoma (1) · Liposarcoma, Myxoid (1) · Lymphoma, Follicular (1)
Neoplasms (7) · Neoplasms by Histologic Type (7) · Neoplasms, Connective Tissue (7) · Neoplasms, Connective and Soft Tissue (7) · Histiocytoma (2) · Neoplasms, Fibrous Tissue (2) · Neoplasms, Muscle Tissue (2) · Neoplasms, Nerve Tissue (2) · Nerve Sheath Neoplasms (2) · Nervous System Diseases (2) · Nervous System Neoplasms (2) · Neurofibroma (2) · Neuromuscular Diseases (2) · Peripheral Nervous System Diseases (2) · Peripheral Nervous System Neoplasms (2)
Docetaxel (1) · Doxorubicin (1) · Gemcitabine (1) · Ipilimumab (1) · Ramucirumab (1) · Trabectedin (1) · atezolizumab (1) · drozitumab (1) · pazopanib (1) · sapanisertib (1) · tazemetostat (1)
Eli Lilly and Company (1) · Epizyme, Inc. (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Genentech, Inc. (1) · Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Ludwig Institute for Cancer Research (1) · National Cancer Institute (NCI) (1)
United States (7) · Australia (3) · Belgium (3) · France (3) · United Kingdom (3) · Germany (2) · Netherlands (2) · Poland (2) · Spain (2) · Austria (1) · Denmark (1) · Hungary (1) · Italy (1) · Japan (1) · Slovakia (1)
James E. Butrynski, MD (1) · Nguyen Binh Bui, MD (1) · Robert G Maki, MD PhD (1) · Sandra Skettino, M.D. (1) · William D Tap (1)
2009 (1), 2015 (1), 2018 (1), 2023 (1), U10CA180821 (1)